[Skip to Content]
[Skip to Content Landing]
Correspondence
May 2013

Surgical Excision After Neoadjuvant Therapy With Vismodegib for a Locally Advanced Basal Cell Carcinoma and Resistant Basal Carcinomas in Gorlin Syndrome

Author Affiliations

Author Affiliation: Department of Dermatology, Stanford University School of Medicine, Redwood City, California.

JAMA Dermatol. 2013;149(5):639-641. doi:10.1001/jamadermatol.2013.30

Vismodegib is useful to treat locally advanced or metastatic basal cell carcinomas (BCCs),1 but to our knowledge, its use as a neoadjuvant to shrink BCCs before surgery has not been reported. This case illustrates the role of vismodegib as a neoadjuvant agent. In addition, this case highlights the fact that a patient with Gorlin syndrome can develop resistant BCCs while taking vismodegib, a phenomenon not widely recognized although recently reported.2

First Page Preview View Large
First page PDF preview
First page PDF preview
×